Clinical Trial Update: A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II clinical trial evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for advanced squamous cell canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Squamous Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)
• HMBD-001

Snippet

Sponsor: Hummingbird Bioscience | Conditions: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING